ProCE Banner Activity

CME

Keeping Pace With the Evolving Treatment Landscape of Immunotherapy in SCLC

In this interactive, on-demand Webcast, lung cancer experts review the evolving role of immunotherapy in the treatment of small-cell lung cancer, including patient case discussions and discussion of new data from the 2020 ASCO Virtual Scientific Meeting.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: August 26, 2020

Expiration: August 25, 2021

No longer available for credit.

Share

Faculty

Anna F. Farago

Anna F. Farago, MD, PhD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Assistant in Medicine
Division of Hematology/Oncology
Department of Medicine
Massachusetts General Hospital
Boston, Massachusetts

Taofeek K. Owonikoko

Taofeek K. Owonikoko, MD, PhD

Professor
Department of Hematology and Medical Oncology
Co-Leader, Thoracic Oncology
Emory University
Atlanta, Georgia

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Genentech, a member of the Roche Group

Merck Sharp & Dohme Corp.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with lung cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the role of combination approaches to optimize checkpoint inhibitor efficacy and reduce treatment resistance in patients with SCLC
  • Plan treatment strategies for patients with extensive-stage SCLC that include immune checkpoint inhibitor combinations
  • Evaluate the available clinical data on biomarkers of response to immune checkpoint inhibitor combinations in SCLC
  • Manage immune-related adverse events in patients with advanced SCLC receiving immune checkpoint inhibitor therapy
  • Incorporate investigational immunotherapy-based combinations and clinical trial participation as part of clinical care strategies for patients with SCLC

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

Anna F. Farago, MD, PhD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Assistant in Medicine
Division of Hematology/Oncology
Department of Medicine
Massachusetts General Hospital
Boston, Massachusetts

Anna F. Farago, MD, PhD, has disclosed that she has received funds for research support from AstraZeneca, Bayer, Bristol-Myers Squibb, Genentech, Merck, PharmaMar, and Roche and consulting fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Genentech, H3 Biomedicine, Merck, Pfizer, Roche, and Syros.

Taofeek K. Owonikoko, MD, PhD

Professor
Department of Hematology and Medical Oncology
Co-Leader, Thoracic Oncology
Emory University
Atlanta, Georgia

Taofeek K. Owonikoko, MD, PhD, has disclosed that he has received funds for research support paid to his institution from AbbVie, Aeglea, Amgen, Astellas, AstraZeneca/MedImmune, Bayer, Bristol-Myers Squibb, Celgene, Corvus, Fujifilm, G1 Therapeutics, Incyte, Loxo/Lilly, Merck, Novartis, Pfizer, Regeneron, Stemcentrx, and United Therapeutics; has received consulting fees from AbbVie, Amgen, ARMO, AstraZeneca, Bayer, BerGenBio, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, EMD Serono, G1 Therapeutics, Heron, Lilly, MedImmune, Novartis, PharmaMar, Sandoz, Seattle Genetics, Takeda, and Xcovery; has received fees for non-CME/CE services from EMD Serono and Roche/Genentech; and has ownership interests in Cambium.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.

Kiran Mir-Hudgeons, PhD

Clinical Editor

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 26, 2020, through August 25, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge, confidence, and competence of learners to integrate immune checkpoint inhibitors into the treatment of patients with SCLC.